| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | OSI-027 | GDSC1000 | pan-cancer | AAC | -0.031 | 0.3 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.3 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | -0.048 | 0.3 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.059 | 0.3 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.031 | 0.3 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |